Danaher Corporation

Day range

$225.60 – $230.66

Open

$229.17

Prev close

$229.75

Volume

3.94M

Market cap

$161.51B

Shares out

702.99M

P/E

37.29

P/S

6.31

P/B

3.01

P/FCF

28.20

ROE

8.1%

ROA

4.6%

Debt/Equity

0.49

Div yield

0.63%

As of Oct 22, 2026

• Earnings and performanceOct 21, 2026

  On October 21, 2026, Danaher Corporation ("Danaher") issued a press release announcing financial results for the quarter ended September 25, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

• Board of directorsOct 13, 2026

  On October 9, 2026, the Board of Directors (the "Board") of Danaher Corporation ... increased the size of the Board to thirteen members and appointed Daniel L. Comas and Robert M. Hershberg to the Board, in each case effective immediately. ... Dr. Hershberg has also been appointed to serve as a member of the Science and Technology Committee of the Board.

• Executive leadershipAug 3, 2026

  Upon the Employment Separation Date, Mr. Blair will be entitled to receive (i) a cash amount equal to 12 months of base salary at the current monthly rate, payable in accordance with the Blair Transition Letter, (ii) a lump-sum cash amount equal to his current target annual cash incentive, payable within 30 calendar days following the effectiveness of a release, and (iii) a lump-sum COBRA subsidy payment equal to the amount the Company would otherwise have contributed toward his group health, prescription, vision and dental coverage as an active employee for 12 months.

• Debt activityJun 3, 2026

  On June 3, 2026, Danaher Corporation and its wholly owned subsidiary DH Masi Finance Inc. entered into a note purchase and guaranty agreement relating to the issuance and sale of (i) CHF 119,500,000 aggregate principal amount of the Issuer's 1.65% Senior Notes, Series A due June 3, 2031, (ii) CHF 137,410,000 aggregate principal amount of the Issuer's 1.88% Senior Notes, Series B due June 3, 2033, (iii) CHF 221,300,000 aggregate principal amount of the Issuer's 2.10% Senior Notes, Series C due June 3, 2036, (iv) CHF 372,660,000 aggregate principal amount of the Issuer's 2.25% Senior Notes, Series D due June 3, 2038, (v) CHF 648,010,000 aggregate principal amount of the Issuer's 2.38% Senior Notes, Series E due June 3, 2041, (vi) CHF 502,060,000 aggregate principal amount of the Issuer's 2.51% Senior Notes, Series F due June 3, 2046, and (vii) CHF 382,000,000 aggregate principal amount of the Issuer's 2.50% Senior Notes, Series G due June 3, 2056.

• Shareholder meetingsMay 7, 2026

  The Company's annual meeting of shareholders was held on May 5, 2026. At the annual meeting, the Company's shareholders voted on the following proposals: 1. To elect the eleven directors named in the Company's proxy statement to terms expiring in 2027. Each nominee for director was elected by a vote of the shareholders as follows: [detailed voting results for all eleven directors]

• TMOThermo Fisher Scientific, Inc.-0.40%
• CSLCarlisle Companies, Inc.-2.14%
• GFFGriffon Corp+0.04%
• CRCrane Company-3.26%
• TMOThermo Fisher Scientific, Inc.-0.40%
• AAgilent Technologies Inc.-0.47%
• RGENRepligen Corp-1.00%
• MTDMettler-Toledo International-0.85%

Days to cover

1.8

Short interest

8.97M

Avg volume

5.11M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• LH vs. DHR: Which Stock Is the Better Value Option?
  positiveZacks Investment Research· Oct 22, 2026
• Company News for Oct 22, 2026
  positiveZacks Investment Research· Oct 22, 2026
• DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line
  positiveZacks Investment Research· Oct 21, 2026
• Danaher (DHR) Tops Q3 Earnings and Revenue Estimates
  positiveZacks Investment Research· Oct 21, 2026
• Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
  positiveZacks Investment Research· Oct 16, 2026